<DOC>
	<DOCNO>NCT01867073</DOCNO>
	<brief_summary>OPB-51602 novel oral small molecule STAT3 inhibitor develop Otsuka Pharmaceutical Company , Ltd , currently undergo clinical investigation National University Health System ( NUHS ) , Singapore . The propose correlative pharmacodynamic pharmacogenetic biomarker study initiate funded investigator , conduct conjunction extension phase I protocol OPB-51602 patient advance solid tumour ( Study code 266-09-801-01/ DSRB protocol B/09/514 ) . All biomarker pharmacogenetic sample collect , store analyse local laboratory study site ( Cancer Science Institute , National University Health System , Singapore , Dr Boon-Cher Goh ) .</brief_summary>
	<brief_title>A Clinical Pharmacodynamic Pharmacogenetic Study OPB-51602 Patients With Advanced Solid Tumours</brief_title>
	<detailed_description />
	<criteria>Advanced Solid Tumor Non advance solid tumor</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>